JP6730271B2 - インターフェロンα２Ｂバリアント - Google Patents

インターフェロンα２Ｂバリアント Download PDF

Info

Publication number
JP6730271B2
JP6730271B2 JP2017523394A JP2017523394A JP6730271B2 JP 6730271 B2 JP6730271 B2 JP 6730271B2 JP 2017523394 A JP2017523394 A JP 2017523394A JP 2017523394 A JP2017523394 A JP 2017523394A JP 6730271 B2 JP6730271 B2 JP 6730271B2
Authority
JP
Japan
Prior art keywords
ifnα2b
seq
antibody
fusion polypeptide
deglycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017523394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534282A5 (https=
JP2017534282A (ja
Inventor
コレット・ベーレンス
アンソニー・ドイル
アダム・クラーク
マシュー・ポラード
テレサ・ドマガラ
Original Assignee
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55851917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6730271(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014904326A external-priority patent/AU2014904326A0/en
Application filed by テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド filed Critical テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド
Publication of JP2017534282A publication Critical patent/JP2017534282A/ja
Publication of JP2017534282A5 publication Critical patent/JP2017534282A5/ja
Priority to JP2020046259A priority Critical patent/JP6957666B2/ja
Application granted granted Critical
Publication of JP6730271B2 publication Critical patent/JP6730271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2017523394A 2014-10-29 2015-10-23 インターフェロンα２Ｂバリアント Active JP6730271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020046259A JP6957666B2 (ja) 2014-10-29 2020-03-17 インターフェロンα２Ｂバリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014904326A AU2014904326A0 (en) 2014-10-29 Interferon alpha 2b variants
AU2014904326 2014-10-29
PCT/AU2015/050654 WO2016065409A1 (en) 2014-10-29 2015-10-23 INTERFERON α2B VARIANTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020046259A Division JP6957666B2 (ja) 2014-10-29 2020-03-17 インターフェロンα２Ｂバリアント

Publications (3)

Publication Number Publication Date
JP2017534282A JP2017534282A (ja) 2017-11-24
JP2017534282A5 JP2017534282A5 (https=) 2018-11-15
JP6730271B2 true JP6730271B2 (ja) 2020-07-29

Family

ID=55851917

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523394A Active JP6730271B2 (ja) 2014-10-29 2015-10-23 インターフェロンα２Ｂバリアント
JP2020046259A Active JP6957666B2 (ja) 2014-10-29 2020-03-17 インターフェロンα２Ｂバリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020046259A Active JP6957666B2 (ja) 2014-10-29 2020-03-17 インターフェロンα２Ｂバリアント

Country Status (18)

Country Link
US (3) US10544199B2 (https=)
EP (1) EP3212216A4 (https=)
JP (2) JP6730271B2 (https=)
KR (1) KR102639037B1 (https=)
CN (1) CN107106656B (https=)
AU (1) AU2015337858B2 (https=)
CA (1) CA2965414C (https=)
CL (1) CL2017001070A1 (https=)
CO (1) CO2017004318A2 (https=)
EA (1) EA037749B1 (https=)
IL (1) IL251822B2 (https=)
MX (1) MX393988B (https=)
PE (1) PE20170908A1 (https=)
PH (1) PH12017500785A1 (https=)
SG (1) SG11201703251TA (https=)
UA (1) UA125637C2 (https=)
WO (1) WO2016065409A1 (https=)
ZA (1) ZA201702891B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020103319A (ja) * 2014-10-29 2020-07-09 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド インターフェロンα２Ｂバリアント

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2015007536A2 (en) * 2013-07-18 2015-01-22 Vib Vzw Fusokines involving cytokines with strongly reduced receptor binding affinities
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
US11001631B2 (en) * 2016-02-05 2021-05-11 Orionis Biosciences BV Clec9A binding agents
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
JP7241677B2 (ja) * 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
US20200354424A1 (en) * 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
JP2021513361A (ja) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ，インコーポレイテッド 線維芽細胞結合物質およびその使用
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
US12162947B2 (en) 2018-09-04 2024-12-10 Nanjing Umab-Biopharma Co., Ltd. Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection
WO2020048454A1 (zh) * 2018-09-04 2020-03-12 南京优迈生物科技有限公司 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
AR117715A1 (es) 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
US11767353B2 (en) * 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
CA3228064A1 (en) * 2021-08-12 2023-02-16 Shanghai Jmt-Bio Technology Co., Ltd. Gpc3-targeted antibody interferon .alpha. fusion protein and use thereof
EP4525911A1 (en) * 2022-05-18 2025-03-26 Takeda Pharmaceutical Company Limited Anti-cd38 fusion protein formulation
EP4532010A1 (en) 2022-05-27 2025-04-09 Takeda Pharmaceutical Company Limited Dosing of cd38-binding fusion protein
TW202430548A (zh) 2022-09-29 2024-08-01 日商武田藥品工業股份有限公司 Ｃｄ３８結合融合蛋白組合療法
AR132623A1 (es) 2023-05-08 2025-07-16 Hoffmann La Roche PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CZ292061B6 (cs) 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
ES2167391T3 (es) 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
SK150298A3 (en) 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
DK1121382T3 (da) 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
ES2558160T3 (es) 1998-12-09 2016-02-02 Phyton Holdings, Llc Glicoproteínas que tienen glicosilación de tipo humano
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
CA2362670A1 (en) 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
AU2001265418B2 (en) 2000-06-22 2006-03-30 Biogen Idec Inc. Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
WO2003066661A2 (en) 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1471938A4 (en) 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
EP1539950A1 (en) 2002-09-09 2005-06-15 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004074486A2 (en) 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
US7338933B2 (en) * 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX2007014889A (es) 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
EP1909822B1 (en) 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants
AU2006270009A1 (en) 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
WO2007044892A2 (en) 2005-10-10 2007-04-19 American Diagnostica, Inc. Upar-binding molecule-drug conjugates and uses thereof
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
AU2006308648A1 (en) 2005-10-31 2007-05-10 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
FR2905375A1 (fr) 2006-08-29 2008-03-07 Biomethodes Sa Variants ameliores de l'interferon alpha humain
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
US8248984B2 (en) 2007-06-20 2012-08-21 I Squared Llc System and method for interfacing devices
CA2694055A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
WO2009017823A2 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
US20100261275A1 (en) * 2007-12-10 2010-10-14 Yves Durocher Production of Recombinant Interferon Proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2710453C (en) 2007-12-26 2019-07-02 Biotest Ag Agents targeting cd138 and uses thereof
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
CA2769276A1 (en) 2009-03-16 2010-09-23 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
US8909257B2 (en) 2010-06-19 2014-12-09 Qualcomm Incorporated Positioning protocol conveyance
SI2621531T1 (sl) 2010-09-27 2017-06-30 Morphosys Ag Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl
WO2012083370A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX2014003689A (es) * 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
SG10201603411WA (en) * 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN104245734B (zh) 2012-01-20 2017-09-05 非营利性组织佛兰芒综合大学生物技术研究所 靶向突变体α‑螺旋束细胞因子
ES2800426T3 (es) * 2012-03-03 2020-12-30 Immungene Inc Moléculas de fusión anticuerpos-mutante de interferón modificadas
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
WO2014114582A2 (de) 2013-01-25 2014-07-31 Bayer Materialscience Ag Sicherheitselement mit volumenhologramm und druckmerkmal
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2965414C (en) * 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
JP7241677B2 (ja) * 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020103319A (ja) * 2014-10-29 2020-07-09 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド インターフェロンα２Ｂバリアント

Also Published As

Publication number Publication date
IL251822A0 (en) 2017-06-29
CL2017001070A1 (es) 2018-01-26
JP2017534282A (ja) 2017-11-24
US10544199B2 (en) 2020-01-28
EA037749B1 (ru) 2021-05-18
UA125637C2 (uk) 2022-05-11
WO2016065409A1 (en) 2016-05-06
AU2015337858A1 (en) 2017-05-11
JP2020103319A (ja) 2020-07-09
MX393988B (es) 2025-03-24
MX2017005481A (es) 2017-10-26
CO2017004318A2 (es) 2017-09-20
KR102639037B1 (ko) 2024-02-20
PH12017500785A1 (en) 2017-10-02
IL251822B2 (en) 2023-03-01
ZA201702891B (en) 2018-08-29
KR20170077185A (ko) 2017-07-05
US20220220184A1 (en) 2022-07-14
PE20170908A1 (es) 2017-07-12
SG11201703251TA (en) 2017-05-30
BR112017008880A2 (pt) 2018-07-10
JP6957666B2 (ja) 2021-11-02
IL251822B (en) 2022-11-01
CA2965414C (en) 2024-01-09
EP3212216A4 (en) 2018-04-18
CN107106656A (zh) 2017-08-29
CN107106656B (zh) 2025-08-26
AU2015337858B2 (en) 2020-09-24
NZ731203A (en) 2024-09-27
EA201790934A1 (ru) 2017-09-29
EP3212216A1 (en) 2017-09-06
US20200102364A1 (en) 2020-04-02
CA2965414A1 (en) 2016-05-06
US11319356B2 (en) 2022-05-03
US20160122410A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
JP6957666B2 (ja) インターフェロンα２Ｂバリアント
US12258401B2 (en) Anti-CD47 combination therapy
JP7111669B2 (ja) ポリペプチド構築物およびその使用
WO2018014068A9 (en) Attenuated type i ifn cd47 combination therapy
JP2024512478A (ja) Ｂリンパ球特異的アマトキシン抗体コンジュゲート
AU2015367224B2 (en) IL-21 antibodies
JP7811028B2 (ja) ヒトｃｘｃｌ１６抗体およびその使用
BR112017008880B1 (pt) POLIPEPTÍDEO DE FUSÃO, COMPOSIÇÃO, USO DO POLIPEPTÍDEO DE FUSÃO E MÉTODO DE GERAÇÃO DE UM POLIPEPTÍDEO DE FUSÃO DE LIGANTE POLIPEPTÍDICO-IFNa2b ATENUADO EM CÉLULAS DE MAMÍFEROS
JP2026500540A (ja) Ｃｄ４５を標的とする抗体
CN120112549A (zh) 具有增强的效应子功能的糖基工程化Fc变体多肽

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200702

R150 Certificate of patent or registration of utility model

Ref document number: 6730271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250